LETROZOLE, ELACESTRANT, ANASTROZOLE, EXEMESTANE, TAMOXIFEN, ELACESTRANT
STML-ELA-0422
Phase 3 small_molecule active
Quick answer
LETROZOLE, ELACESTRANT, ANASTROZOLE, EXEMESTANE, TAMOXIFEN, ELACESTRANT for Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer with High Risk of Recurrence is a Phase 3 program (small_molecule) at Stemline Therapeutics B.V. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Stemline Therapeutics B.V.
- Indication
- Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer with High Risk of Recurrence
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active